Market Closed -
OTC Markets
03:55:31 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
0.85
USD
|
+6.25%
|
|
-.--%
|
-29.17%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
421.7
|
294.4
|
159.8
|
60.91
|
3.943
|
2.805
|
2.805
|
-
|
Enterprise Value (EV)
1 |
421.7
|
294.4
|
159.8
|
60.91
|
3.943
|
2.805
|
2.805
|
2.805
|
P/E ratio
|
-8.28
x
|
-5.49
x
|
-4.63
x
|
-0.74
x
|
-0
x
|
-0.11
x
|
-0.12
x
|
-0.13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-7,466,700
x
|
-5,673,807
x
|
-1,735,863
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
878
|
1,000
|
1,004
|
2,156
|
2,166
|
3,301
|
3,301
|
-
|
Reference price
2 |
480.4
|
294.4
|
159.2
|
28.25
|
1.820
|
0.8500
|
0.8500
|
0.8500
|
Announcement Date
|
3/8/19
|
3/6/20
|
3/12/21
|
3/30/22
|
3/31/23
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-47.56
|
-50.56
|
-33.46
|
-66.02
|
-34.42
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-47.06
|
-50.87
|
-34.58
|
-66.73
|
-36.06
|
-
|
-
|
-
|
Net income
|
-47.18
|
-50.87
|
-34.58
|
-66.73
|
-36.06
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-58.00
|
-53.60
|
-34.40
|
-38.00
|
-666.0
|
-7.910
|
-7.390
|
-6.650
|
Free Cash Flow
|
-
|
-39.43
|
-28.17
|
-35.09
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/8/19
|
3/6/20
|
3/12/21
|
3/30/22
|
3/31/23
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-35.73
|
-10.24
|
-11.63
|
-10.95
|
-10.3
|
-7.142
|
-6.028
|
-5.483
|
-4.14
|
-3.637
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-36.06
|
-9.885
|
-12.09
|
-11.62
|
-10.62
|
-7.508
|
-6.319
|
-6.23
|
-4.341
|
-3.592
|
-
|
Net income
|
-36.06
|
-9.885
|
-12.09
|
-11.62
|
-10.62
|
-7.508
|
-6.319
|
-6.23
|
-4.341
|
-3.592
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-21.60
|
-4.400
|
-4.000
|
-5.200
|
-4.800
|
-3.600
|
-3.050
|
-2.880
|
-1.960
|
-1.310
|
-1.430
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/16/21
|
11/8/21
|
3/30/22
|
5/6/22
|
8/12/22
|
11/10/22
|
3/31/23
|
5/12/23
|
8/11/23
|
11/13/23
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-39.4
|
-28.2
|
-35.1
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.24
|
0.04
|
-
|
0.09
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/8/19
|
3/6/20
|
3/12/21
|
3/30/22
|
3/31/23
|
-
|
-
|
-
|
Last Close Price
0.85
USD Average target price
30
USD Spread / Average Target +3,429.41% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.17% | 2.81M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|